The Life Sciences team advised Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) on its underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $35.00 per share, or approximately $253.8 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 1,087,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering closed on August 16, 2022.
The team also advised Cerevel on its pricing of $300.0 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a concurrent private placement to qualified institutional buyers, in an offering exempt from registration under the Securities Act of 1933, as amended. In connection with the notes offering, Cerevel granted the initial purchasers of the notes a 13-day option to purchase up to an additional $45.0 million aggregate principal amount of the notes. The offering of common stock is not contingent upon the consummation of the concurrent offering of the notes, and the concurrent offering of the notes is not contingent upon the consummation of the offering of common stock. The concurrent offering of the notes closed on August 16, 2022.
Cerevel is clinical-stage biopharmaceutical company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases.
The Goodwin team was led by Jim Barri, Yana Shneyderman, Della Fok, Karin Yoo, John Servidio, Patrick Wilson, Alex Apostolopoulos, Nicole Spiteri, Elizabeth Mulkey, Roger Cohen, Heath Ingram, Jud Welle, and Ettore Santucci, with invaluable assistance from Sara Lepis.
For more details, read the press release and article in Endpoints News.